Select Your Language

Indian Pharma Market

India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors Without Borders, the UNCTAD etc.Presently there are 10,500 manufacturing units and over 3,000 pharma companies in India, growing at an exceptional rate. India has about 1,400 WHO GMP approved manufacturing units. India has been accredited with approximately 1,105 CEPs, more than 950 TGA approvals and 584 sites approved by the USFDA. Globally more than 90 per cent of formulations approvals for Anti-retroviral (ARVs), Anti-tubercular & Anti-malarial (WHO pre-qualified) have been granted to India.Manufacturing costs in India are approximately 35-40 per cent of those in the US due to low installation and manufacturing costs. India ranks amongst the top global generic formulation exporters in volume terms. India’s pharma exports stood at US$ 15 billion in 2013-14.

India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines.The country’s pharmaceutical industry accounts for about 1.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms. The Government of India has announced a host of measures to create a facilitating environment for the Indian pharmaceutical industry. The policies of the Government of India are aimed at building more hospitals, boosting local access to healthcare, improving the quality of pharmaceuticals and improving the quality of medical training. The Government of India is committed to setting up robust healthcare and delivery mechanisms.India’s pharma sales are expected to reach US$ 27 billion by 2016. India is well placed to become one of the major drivers in providing healthcare to all while controlling the ever-increasing healthcare spend of both developed and developing nations.

Glenmark, Torrent, Sanofi, Dr Reddy’s and Cipla grew in excess of 25% Glenmark reported highest growth in April at 30.1% while 4Q growth stood at 24% YoY on improved traction across therapies.

Torrent (28.7% YoY), Sanofi (25.8% YoY), Dr. Reddy’s Lab (25.8% YoY) and Cipla (25.1%) also outperformed the IPM growth in April (4Q growth was also in excess of 20% YoY). Post Sun+Ranbaxy merger, the combined entity (Sun) sales grew 18% YoY in April and 12.6% in 4Q. Sun Pharma on standalone basis grew 27% YoY while Ranbaxy portfolio grew 6% YoY.

Most of the therapies grew in double digits in April 2015 Gastro-Intestinal (21% YoY), Anti-Diabetic (25% YoY) and Derma (22% YoY) grew in excess of 20% in April. In Derma, growth for Betnovate C, Candid, Lobate GM brands were higher at 89.5% YoY, 43.3% and 41.7% respectively. Spasmo Proxyvon Plus, a leading brand in Gastro therapy in India, grew 113% YoY in April and MAT growth stood at 100% YoY. Other therapies which registered double digit growth in April include - Respiratory (17.8% YoY), Cardiac (16% YoY), Pain/Analgesic (16% YoY) and Neuro/CNS (15.5% YoY).